 China Biologic Products Holdings, Inc. NASDAQ: CBPO, China Biologic or the Company, a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. Xinjiang Deyuan to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic. In addition, the Company announced that, through the lawsuits it previously filed against Xinjiang Deyuan, the Company is seeking monetary claims totaling over RMB460 million and has obtained judicial freezing of certain shares of Xinjiang Deyuan and certain of its plasma collection stations. China Biologic will continue to take all necessary legal measures to vigorously protect its rights. 